Overview
Vicor Technologies, Inc. (OTCBB: VCRT) creates innovative, non-invasive diagnostics based on its patented PD2i® nonlinear algorithm, a new vital sign which accurately determines the likelihood of pathological events in specific populations.
Vicor is currently in the process of commercializing its first three products:
- The PD2i Analyzer™ measures heart trate variability in patients at rest, and in response to controlled exercise and paced respiration.
- The PD2i CA™ (Cardiac Analyzer) identifies cardiovascular disease patients at risk of death from arrhythmia or pump failure.
- The PD2i VS™ (Vital Sign) quickly evaluates critically-injured soldiers and civilians to improve triage and survivability. The PD2i VS™ is in ongoing trials in collaboration with the U.S. Army Institute of Surgical Research (USAISR).
Vicor has 510(k) marketing clearance from the FDA for the PD2i Analyzer™. Existing CPT codes provide physicians with reimbursement and a source of revenue for Vicor. Vicor expects additional clearances for the PD2i CA™ (for cardiac death), PD2i VS™ (for trauma triage), in 2010.
Vicor anticipates additional applications for other disorders and diseases for the PD2i® nonlinear algorithm and software.
Vicor Therapeutics discovers, develops and commercializes new drugs based on unique compounds Vicor scientists have isolated from hibernating animals. In animal trials, these compounds show great promise to be able to mitigate stroke, infarction, kidney failure, obesity, and other medical challenges.
Vicor suspended research on its Therapeutics platform in 2003 to conserve cash and focus on the commercialization of the PD2i Analyzer™. Vicor Therapeutics remains in the pre-clinical testing phase while the company awaits patent issuances and sufficient funding to enable continuation.
